WASHINGTON, Sept. 8, 2015 (GLOBE NEWSWIRE) -- The Association of Clinical Research Organizations (ACRO) is kicking off its second annual CRO Innovation Month with the theme of "Transforming Patient Centered Drug Development." A series of videos describing how CROs are educating and engaging patients while implementing their suggestions into the clinical research process will debut this month with thoughts from subject matter experts from ACRO member companies.
"Incorporating the patient perspective into clinical trials is essential for ACRO members as they work to improve the quality and efficiency of clinical trials while ultimately helping to deliver better outcomes for patients," said Doug Peddicord, Executive Director of ACRO. "Our members have enthusiastically embraced this new paradigm of drug development, as this video series demonstrates."
Peddicord added: "Stay tuned throughout the Fall as ACRO will be releasing a number of videos focused on topics such as: the importance of real world data for sponsors, regulators, and payers; promoting diversity in clinical trials; the patient's perspective on clinical trial participation; and CRO efforts to collaborate to improve the drug development process. Policymakers and regulators globally are weighing in on these topics and CROs, with the pivotal role they play in the drug development process, are well-positioned to inform and influence these discussions."
About ACRO
The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics, and medical devices. The Association provides an active voice for the CRO industry globally. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ approximately 110,000 professionals worldwide and conduct research in 142 countries. For more information, please visit www.acrohealth.org. Twitter @acrohealth. YouTube @ACROHealthChannel. Facebook. RebelMouse.